Fig. 2From: Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancerClinical effects of eribulin chemotherapy. Kaplan-Meier curves of the indicated clinical effects of eribulin chemotherapy are shown. The clinical effects were as follows: median overall survival (OS) = 334 days a; median time to treatment failure (TTF) = 81 days b; and median progression-free survival (PFS) = 275 days c Back to article page